Plant Name: Salix rosmarinifolia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.730E-14 | 3.767E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.739E-13 | 1.893E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 5.060E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.394E-11 | 5.060E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.302E-11 | 7.162E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.431E-11 | 9.339E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.661E-10 | 3.013E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.114E-10 | 6.399E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.794E-09 | 4.131E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 1.739E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 1.129E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.955E-06 | 1.252E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, RAB9A |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.431E-06 | 1.512E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 3.059E-06 | 1.800E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.054E-06 | 1.800E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 3.164E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.017E-05 | 5.031E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.524E-05 | 6.914E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.132E-05 | 8.929E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 2.132E-05 | 8.929E-03 | ABCB1, ABCG2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.460E-10 | 4.963E-09 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.578E-09 | 4.383E-08 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.373E-09 | 9.490E-08 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.699E-08 | 1.444E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.733E-07 | 3.219E-06 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.028E-07 | 3.416E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.252E-06 | 4.008E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.627E-05 | 6.913E-05 | CYP1A1; CYP1B1; CYP19A1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.680E-05 | 1.768E-04 | ABCB1; CYP3A4; ABCG2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.019E-03 | 3.149E-03 | CYP2C9; CYP1A2; CYP1A1; CYP2C19; CYP3A4; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.733E-03 | 4.910E-03 | CYP2C9; CYP2C19 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 8.764E-04 | 2.980E-03 | ABCB1; ABCG2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.529E-03 | 1.343E-02 | CYP2C9; CYP2C19 |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 1.262E-02 | 2.861E-02 | SMN2; SMN1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.991E-03 | 1.305E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | KCNA3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; ADORA3; ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic arthritis | L40.5, M07 | KCNA3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |